• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Dermatol . First reported case of thymoma-associated multiorgan autoimmunity induced by COVID-19

tetano

Editor, Senior Moderator
J Dermatol


. 2024 Oct 26.
doi: 10.1111/1346-8138.17519. Online ahead of print. First reported case of thymoma-associated multiorgan autoimmunity induced by COVID-19

Rie Hyobu[SUP] 1 [/SUP], Miho Mori[SUP] 1 [/SUP], Tatsuo Maeda[SUP] 1 [/SUP], Kazuki Fujimori[SUP] 1 [/SUP], Yukako Shimai[SUP] 1 [/SUP], Makiko Naito[SUP] 2 [/SUP], Masayuki Masuda[SUP] 2 [/SUP], Tatsuo Ohira[SUP] 3 [/SUP], Norihiko Ikeda[SUP] 3 [/SUP], Yukari Okubo[SUP] 1 [/SUP], Kazutoshi Harada[SUP] 1 [/SUP]



Affiliations
Abstract

Thymoma-associated multiorgan autoimmunity (TAMA) presents with skin symptoms similar to those of graft-versus-host disease (GVHD), liver dysfunction, and enteritis, in the absence of a history of hematopoietic stem cell or bone marrow transplantation. TAMA is a type of paraneoplastic syndrome associated with thymoma. Its etiology is unclear but is thought to be a result of breakdown of immune tolerance. Histopathologically, TAMA is characterized by epidermal acanthosis with parakeratosis, individual cell keratinization, liquefaction degeneration, and intraepidermal infiltration of CD8-positive lymphocytes. A 64-year-old female patient with a history of myasthenia gravis and thymoma treated with prednisolone (10 mg/day) and cyclosporine (150 mg/day) experienced erythema on her trunk after coronavirus disease 2019 (COVID-19) onset. A psoriatic drug eruption was suspected and the possible causative drug was discontinued, but the skin rash failed to improve. A skin biopsy demonstrated GVHD-like histopathological findings. Diarrhea, abdominal pain, and duodenal perforation occurred concurrently, leading to the diagnosis of TAMA. Thereafter, the patient continued prednisolone and cyclosporine in the same doses as the TAMA treatment and added topical steroids. During the disease course, candida fungemia and cytomegalovirus infection developed, resulting in the patient's death. The TAMA was considered to have been caused by the release of inflammatory cytokines, autoreactive T cell activation, and regulatory T cell dysfunction induced by COVID-19.

Keywords: COVID‐19; alopecia; graft‐versus‐host disease; myasthenia gravis; thymoma.

 
Back
Top Bottom